Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI5752 in Advanced Solid Tumors
NCT03530397Phase 1Active, not recruiting
- Sponsor
- MedImmune
- Start
- Apr 2018
- Primary completion
- Jul 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, randomised, open-label trial of volrustomig in solid tumor (advanced stage) (3 arms), sponsored by MedImmune. Primary endpoints: Adverse Events, Objective Response Rate up to 2 years and 1 more. Started Apr 2018; status: active, not recruiting.
02
Drugs
volrustomig
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03530397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03530397.